Welcome to our dedicated page for DEVONIAN HEALTH GROUP news (Ticker: DVHGF), a resource for investors and traders seeking the latest updates and insights on DEVONIAN HEALTH GROUP stock.
Devonian Health Group Inc. (TSXV: GSD, OTCQB: DVHGF) is a clinical stage pharmaceutical and biopharmaceutical company that regularly issues news related to its development of prescription drugs for auto-immune inflammatory and fibroinflammatory diseases. As a medicinal and botanical manufacturing company with a focus on prescription botanical drug products, its updates often center on scientific progress, clinical programs and corporate developments.
News coverage for Devonian frequently highlights advances with its lead candidate Thykamine™, the first pharmaceutical product from its SUPREX™ platform. Releases have described comparative in vitro studies against widely used anti-inflammatory drugs, in vivo work in models of MASH and fibrosis, and Phase II clinical data in ulcerative colitis and atopic dermatitis. The company also reports on patent filings, new potential indications and formulation work, such as development of oral forms for gastrointestinal diseases.
Investors and observers can also expect regular financial and corporate news. Devonian publishes quarterly and annual financial results, including commentary on distribution revenues generated by its Altius commercialization subsidiary and on how those revenues support Thykamine™ development. Other announcements cover private placements, stock option grants, changes in officers and directors, shareholder meeting results, option and rights plans, and matters related to financial reporting and exchange approvals.
Because Devonian operates at the intersection of clinical-stage drug development and pharmaceutical distribution in Canada, its news flow combines R&D milestones, regulatory and intellectual property updates, and capital markets activity. Following the DVHGF news stream can help readers track the evolution of its botanical-based pipeline, the status of distribution agreements managed through Altius, and key corporate decisions that shape the company’s long-term strategy.
Devonian Health Group (OTCQB: DVHGF) will participate in Renmark Financial Communications' Virtual Non-Deal Roadshow Series on July 10, 2024, in Los Angeles. The event will feature a presentation by Luc Gregoire, President & CEO of Devonian, covering the latest investor updates, followed by a live Q&A session. Stakeholders and investors are invited to attend the live event via registration, though spaces are A replay will be available on the company’s investor website post-event. Attendees are advised to use the latest version of Google Chrome for optimal connectivity.
Devonian Health Group (TSXV: GSD; OTCQB: DVHGF) announced their participation in Renmark Financial Communications Inc.’s Virtual Non-Deal Roadshow Series in Boston on June 26, 2024. The event will feature the latest investor presentation from Mr. Luc Gregoire, President & CEO of Devonian. Stakeholders, investors, and individuals are invited to register and attend the live session. The presentation will conclude with a live Q&A. live event registration is available, but the replay will be accessible on the company's investor website.
To register, use the provided link and ensure you have the latest version of Google Chrome for optimal connectivity.
Devonian Health Group reported a breakout third quarter for 2024 with a 1,162% year-over-year revenue increase, driven by the launch of DEXLANSOPRAZOLE, a medication for GERD, by its subsidiary, Altius Health Care. For the quarter ending April 30, 2024, the company posted a net loss of $0.374 million, or $0.002 per share, an improvement from the $1.5 million loss, or $0.01 per share, in the same period last year. Year-to-date, distribution revenue rose 583% to $8.68 million, while net losses were reduced to $2.306 million from $3.736 million. Cash reserves stood at $3.5 million, offset by $2.16 million in debt. Key business initiatives included preparations for a phase II/III clinical study of Thykamine for pediatric eczema and the appointment of André Boulet as Chairman of the Board and COO. Additionally, Devonian engaged Renmark Financial Communications for investor relations services.
Devonian Health Group announced the appointment of Dr. André P. Boulet as Chairman of the Board and Chief Operating Officer. Dr. Boulet, the founder of Devonian, has been a Board member since 2015 and the Chief Scientific Officer since August 2022. He brings extensive experience in drug development, regulatory affairs, market access, financing, and restructuring. Dr. Boulet holds multiple degrees, including a Ph.D. in physiology-endocrinology and has completed postdoctoral and health economics training. This strategic leadership change aims to enhance the integration of Devonian's development strategy and manage key stakeholder relationships. Outgoing Chairman David Baker will remain a Board member.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.